FICAN Seminar: Merja Heinäniemi


January 31, 2024    
3:00 pm - 4:00 pm

January 31st at 15:00
Online event

Professor Merja Heinäniemi, Institute of Biomedicine, School of Medicine, Faculty of Health Sciences
Cell state transitions and emergence of drug resistance in cancer

Welcome to the 9th FICAN seminar on Wed. 31. 1.2024 at 15.00 – 16 in Teams. This time the seminar is organized by FICAN East. The seminar will be held online and is open to everyone interested in cancer research.

Click here to join the meeting: JOIN THE MEETING


Get to know the speaker

Systems Genomics – Heinäniemi lab

Drug therapy is designed for targeting a specific molecular state in cells. In our ongoing research, we explore drug therapy in context of the new paradigm that considers transitions into alternative cell states as a central part in treatment design for cancer therapy. We have carried out characterization of cell states in context of the most common childhood cancer, acute lymphoblastic leukemia (ALL).

ALL represents a paradigmatic example of how alterations in transcription factors (TFs) initially block the normal developmental paths. Moreover, a number of recent studies have shown that cell state plasticity presently poses a challenge for treatment success. As TFs represent the master regulators defining cell states and via their regulatory interactions constrain the space of accessible alternative states, our focus has been on abstracting genomics profiles into models of TF activity. More recently, we have also established analysis methodology to examine microRNA gene regulation that impacts cellular homeostasis through post-transcriptional regulation and can thereby play a key role during disease development.

In my talk, I will present recent results from our single cell genomics projects that show how transitions to alternative cell states with aberrant TF activity, re-wired signaling activity, stem cell-like properties, even a lineage switch, can underly a poor treatment response in leukemia. Our goal is to chart such transitions to develop new drug treatment strategies that block this route to treatment resistance to avoid disease recurrence (10-15% of patients) that leads to a dramatic increase in cytotoxic burden, which endangers the life-long health, development and well-being of children. In broader context of cancer therapy our work contributes to the conceptual framework of capturing cell state evolution into predictive models to improve design of preventive measures that address the prevalent emergence of drug resistance in cancer

Everybody welcome!